Translational Cancer Research,
Journal Year:
2024,
Volume and Issue:
13(6), P. 2735 - 2750
Published: June 1, 2024
Esophageal
cancer
is
often
overlooked
in
its
early
stages,
with
approximately
70%
of
patients
being
diagnosed
at
a
locally
advanced
or
late
stage.
Surgical
treatment
and
chemotherapy
are
the
mainstays
esophageal
management.
However,
for
cancer,
both
surgery
alone
have
high
rates
recurrence
metastasis.
The
objective
research
was
to
investigate
security
therapeutic
efficacy
neoadjuvant
immunochemotherapy
(NICT)
resectable,
squamous
cell
carcinoma
(ESCC).
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: Aug. 9, 2024
The
past
few
decades
have
witnessed
the
rise
of
immunotherapy
for
Gastrointestinal
(GI)
tract
cancers.
role
immune
checkpoint
inhibitors
(ICIs),
particularly
programmed
death
protein
1
(PD-1)
and
PD
ligand-1
antibodies,
has
become
increasingly
pivotal
in
treatment
advanced
perioperative
GI
Currently,
anti-PD-1
plus
chemotherapy
is
considered
as
first-line
regimen
unselected
gastric/gastroesophageal
junction
adenocarcinoma
(G/GEJC),
mismatch
repair
deficient
(dMMR)/microsatellite
instability-high
(MSI-H)
colorectal
cancer
(CRC),
esophageal
(EC).
In
addition,
encouraging
performance
claudin18.2-redirected
chimeric
antigen
receptor
T-cell
(CAR-T)
therapy
later-line
cancers
brings
new
hope
cell
solid
tumour
treatment.
Nevertheless,
remains
yet
precise,
researchers
are
dedicated
to
further
maximising
optimising
efficacy.
This
review
summarises
important
research,
latest
progress,
future
directions
including
EC,
G/GEJC,
CRC.
Journal of Hematology & Oncology,
Journal Year:
2025,
Volume and Issue:
18(1)
Published: Jan. 13, 2025
The
tumor
microenvironment
(TME)
is
integral
to
cancer
progression,
impacting
metastasis
and
treatment
response.
It
consists
of
diverse
cell
types,
extracellular
matrix
components,
signaling
molecules
that
interact
promote
growth
therapeutic
resistance.
Elucidating
the
intricate
interactions
between
cells
TME
crucial
in
understanding
progression
challenges.
A
critical
process
induced
by
epithelial-mesenchymal
transition
(EMT),
wherein
epithelial
acquire
mesenchymal
traits,
which
enhance
their
motility
invasiveness
progression.
By
targeting
various
components
TME,
novel
investigational
strategies
aim
disrupt
TME's
contribution
EMT,
thereby
improving
efficacy,
addressing
resistance,
offering
a
nuanced
approach
therapy.
This
review
scrutinizes
key
players
emphasizing
avenues
therapeutically
components.
Moreover,
article
discusses
implications
for
resistance
mechanisms
highlights
current
toward
modulation
along
with
potential
caveats.
Cancer Discovery,
Journal Year:
2024,
Volume and Issue:
14(4), P. 615 - 619
Published: April 4, 2024
Summary:
Liquid
biopsies
are
emerging
as
powerful
minimally
invasive
approaches
that
have
the
potential
to
solve
several
long-standing
problems
spanning
continuum
of
cancer
care:
early
detection
cancer,
minimal
residual
disease
tracking,
and
refinement
heterogeneity
clinical
responses
together
with
therapeutic
response
monitoring
in
metastatic
setting.
Existing
challenges
driven
by
technical
limitations
establishment
value
liquid
represent
fields
active
research
call
for
convergence
science
bridge
scientific
discovery
care.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Dec. 26, 2024
Immune
checkpoint
inhibitors
(ICIs)
have
dramatically
transformed
the
treatment
landscape
for
various
malignancies,
achieving
notable
clinical
outcomes
across
a
wide
range
of
indications.
Despite
these
advances,
resistance
to
immune
blockade
(ICB)
remains
critical
challenge,
characterized
by
variable
response
rates
and
non-durable
benefits.
However,
growing
research
into
complex
intrinsic
extrinsic
characteristics
tumors
has
advanced
our
understanding
mechanisms
behind
ICI
resistance,
potentially
improving
outcomes.
Additionally,
robust
predictive
biomarkers
are
crucial
optimizing
patient
selection
maximizing
efficacy
ICBs.
Recent
studies
emphasized
that
multiple
rational
combination
strategies
can
overcome
enhance
susceptibility
ICIs.
These
findings
not
only
deepen
tumor
biology
but
also
reveal
unique
action
sensitizing
agents,
extending
benefits
in
cancer
immunotherapy.
In
this
review,
we
will
explore
underlying
ICIs,
discuss
significance
microenvironment
(TIME)
biomarkers,
analyze
current
outline
alternative
effectiveness
including
personalized
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(2), P. 861 - 861
Published: Jan. 20, 2025
The
treatment
landscape
for
advanced
melanoma
has
transformed
significantly
with
the
advent
of
BRAF
and
MEK
inhibitors
(BRAF/MEKi)
targeting
BRAFV600
mutations,
as
well
immune
checkpoint
(ICI)
like
anti-PD-1
monotherapy
or
its
combinations
anti-CTLA-4
anti-LAG-3.
Despite
that,
many
patients
still
do
not
benefit
from
these
treatments
at
all
develop
resistance
mechanisms.
Therefore,
prognostic
predictive
biomarkers
are
needed
to
identify
who
should
switch
escalate
their
strategies
initiate
an
intensive
follow-up.
In
melanoma,
liquid
biopsy
shown
promising
results,
a
potential
role
in
predicting
relapse
resected
high-risk
disease
monitoring
during
disease.
Several
components
peripheral
blood
have
been
analyzed,
such
circulating
tumor
cells
(CTCs),
cell-free
DNA
(cfDNA),
circulant
tumoral
(ctDNA),
which
turned
out
be
particularly
promising.
To
analyze
ctDNA
blood,
different
techniques
proven
useful,
including
digital
droplet
polymerase
chain
reaction
(ddPCR)
detect
specific
mutations
and,
more
recently,
next-generation
sequencing
(NGS)
techniques,
allow
analyzing
broader
repertoire
mutation
each
patient.
this
review,
our
goal
is
update
current
understanding
biopsy,
focusing
on
use
biological
material
daily
clinical
management
patients,
particular
those
treated
ICI.
Journal of Surgical Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 5, 2025
Standard
treatment
of
patients
with
stage
II/III
esophageal
or
gastroesophageal
junction
(E/GEJ)
cancer
involves
neoadjuvant
chemoradiation
(nCRT),
resection,
and
immunotherapy.
Our
trial
evaluated
the
addition
perioperative
avelumab
to
standard
treatments.
Immunological Medicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 12
Published: Jan. 17, 2025
Immune
checkpoint
molecules,
including
both
co-inhibitory
molecules
and
co-stimulatory
are
known
to
play
critical
roles
in
regulating
T-cell
responses.
During
the
last
decades,
immunotherapies
targeting
these
(such
as
programmed
cell
death
1
(PD-1),
lymphocyte
activation
gene
3
(LAG-3))
have
provided
clinical
benefits
many
cancers.
It
is
becoming
apparent
that
not
only
T
cells,
but
also
B
cells
a
capacity
express
some
molecules.
These
were
originally
thought
be
markers
for
regulatory
which
produce
IL-10,
recent
studies
suggest
(especially
immunoglobulin
mucin
domain
(TIM-1),
immunoreceptor
with
Ig
ITIM
domains
(TIGIT),
PD-1)
can
regulate
intrinsic
B-cell
functions.
Here,
we
focus
on
summarize
their
characteristics,
ligands,
functions
cells.
IntechOpen eBooks,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 21, 2025
The
ErbB/HER
family
has
an
essential
role
in
tumor
progression,
proliferation,
invasion,
metastasis,
and
migration.
ErbB/HER-targeted
therapeutic
agents
have
emerged
as
effective
options
to
achieve
excellent
clinical
outcomes
boost
cancer
drug
discovery
by
enhancing
treatment
efficacy,
lowering
resistance,
minimizing
systemic
toxicity.
Furthermore,
combination
therapy
targeting
members,
well
hormonal
therapy,
chemotherapy,
immunotherapy,
radiotherapy,
also
enhances
effects
for
immunology.
Zinc-finger
nucleases
(ZFNs),
transcription
activator-like
effector
(TALENs),
Clustered
Regularly
Interspaced
Short
Palindromic
Repeats-CRISPR-Associated
9
(CRISPR-Cas9)
comprise
powerful
tools
redefining
the
boundaries
of
research.
In
this
chapter,
we
provide
a
comprehensive
evaluation
anti-cancer
single
combined
therapeutics
target
which
could
represent
promising
approaches
treatment.
We
discuss
recent
worldwide
advancements
structures,
mechanism,
selectivity,
efficacy
design
development
efforts,
sheds
light
on
their
potential
improving
addition,
highlight
achievements
potentials
ZFNs,
TALENs,
CRISPR/Cas9
immunology,
such
genetic
analysis
manipulation.
customized
application
CRISPR/Cas9-mediated
ErbB2/HER2
inhibited
cell
proliferation
tumorigenicity
opens
up
novel
possibility
